top of page
![Sensirion_edited.jpg](https://static.wixstatic.com/media/d3dc8c_08fbb244389944278db22fcef0636a7a~mv2.jpg/v1/fill/w_497,h_269,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/Sensirion_edited.jpg)
Haya Therapeutics SA
Health & Nutrition
HAYA Therapeutics is developing a proprietary anti-fibrotic therapy for myocardial fibrosis and heart failure by targeting a master regulator of fibrosis in the heart, Wisper. Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. HAYA will also implement a target discovery engine to develop a pipeline of lncRNA anti-fibrotic targets in multiple tissues/indications.
![2000_W1_Carbofix.png](https://static.wixstatic.com/media/d3dc8c_0d4cea7fa3204510a28a705465bfec01~mv2.png/v1/fill/w_180,h_74,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/2000_W1_Carbofix.png)
2019
bottom of page